Biological Psychiatry Global Open Science
2024
Victorita E. Ivan, David P Tomàs-Cuesta, Ingrid M. Esteves et al.
7 citations
The ability of psychedelic compounds to profoundly alter mental function has been long known, but the underlying changes in cellular-level information encoding remain poorly understood. We used two-photon microscopy to record from the retrosplenial cortex in head-fixed mice running on a treadmill before and after injection of the nonclassic psychedelic ibogaine (40 mg/kg intraperitoneally). We...
Biological Psychiatry Global Open Science
October 1, 2023
Ben Julian A Palanca, Charles R Conway, Thomas Zeffiro et al.
Nitrous oxide holds promise in the treatment of major depressive disorder. Its psychotropic effects and NMDA receptor antagonism have led to comparisons with ketamine. Despite longstanding use, persistent effects of nitrous oxide on the brain have not been characterized. Sixteen healthy volunteers were recruited in a double-blind crossover study. In randomized order, individuals underwent a...
Biological Psychiatry Global Open Science
August 1, 2023
Michael M. Tranter, L. Faget, T. Hnasko et al.
Background The orbitofrontal cortex (OFC) is essential for decision making, and functional disruptions within the OFC are evident in schizophrenia. Postnatal phencyclidine (PCP) administration in rats is a neurodevelopmental manipulation that induces schizophrenia-relevant cognitive impairments. We aimed to determine whether manipulating OFC glutamate cell activity could ameliorate postnatal...
Biological Psychiatry Global Open Science
July 2023
Ahmed Hasbi, Bertha K. Madras, Susan R George
Frequent cannabis use is associated with a higher risk of developing cannabis use disorder and other adverse consequences. However, rodent models studying the underlying mechanisms of the reinforcing and withdrawal effects of the primary constituent of cannabis, Δ9-tetrahydrocannabinol (THC), have been limited. This study investigated the effects of daily THC (1 mg/kg, intraperitoneal, 9 days)...
Biological Psychiatry Global Open Science
May 29, 2023
Daisy L. Spark, Sherie Ma, Cameron J. Nowell et al.
5 citations
Background: The development of more effective treatments for schizophrenia targeting cognitive and negative symptoms has been limited, partly due to a disconnect between rodent models and human illness. Ketamine administration is widely used to model symptoms of schizophrenia in both humans and rodents. In mice, subchronic ketamine treatment reproduces key dopamine and glutamate dysfunction;...
Biological Psychiatry Global Open Science
May 1, 2023
Eunhye Park, Hsin-Yi Kao, Hussam Jourdi et al.
Background Phencyclidine (PCP) causes psychosis, is abused with increasing frequency, and was extensively used in antipsychotic drug discovery. PCP discoordinates hippocampal ensemble action potential discharge and impairs cognitive control in rats, but how this uncompetitive NMDA receptor (NMDAR) antagonist impairs cognition remains unknown. Methods The effects of PCP were investigated on...
Biological Psychiatry Global Open Science
April 1, 2023
Katherine H. Karlsgodt
Worldwide, cannabis is more widely used than all other classes of illicit drugs combined (1). Despite the perception of cannabis as a low-risk drug, the proportion of treatment admissions for cannabis, relative to other drugs, is high. In addition, it is the most frequently used illicit drug among adolescents. Compared with a few decades ago, cannabis strains are increasingly potent, while at...
Biological Psychiatry Global Open Science
April 1, 2021
Yujing Zhang, Bing Xie, Yin Yuan et al.
Background Poststroke social isolation could worsen poststroke depression and dampen neurogenesis. (R,S)-ketamine has antidepressant and neuroprotective effects; however, its roles and mechanisms in social isolation–mediated depressive-like behaviors and sensorimotor recovery remain unclear. Methods Mice were subjected to transient middle cerebral artery occlusion, and then were pair-housed...